Last checked at 18 May 2020 09:00
Novacyt S.A.
Â
("Novacyt" or the "Company")
Â
Director/PDMR Shareholdings
Â
Paris, France and Camberley, UK - 18 May 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 15 May 2020, the following Directors purchased ordinary shares of €1/15 each in the Company (the "Ordinary Shares"):
Â
Director | Title | Number of Ordinary Shares purchased | Price paid per Ordinary Share | Resultant beneficial holding | % of issued share capital |
Graham Mullis  | Chief Executive Officer |  9,493  |  310p |  61,631  |  0.09% |
James Wakefield | Non-Executive Director & Chairman | Â 20,000 Â | Â 304.9p | Â 36,839 | Â 0.05% Â |
 Â
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Â
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name |  Graham Mullis, Chief Executive Officer  | ||||
2. | Reason for the Notification | |||||
a) | Position/status | See 1(a) - classified as a PDMR of the Company  | ||||
b) | Initial notification/ Amendment | Initial Notification  | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  | |||||
a) | Name | Novacyt S.A. | ||||
b) | LEI | 213800BWAC2BF295EG28 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | ordinary shares of €1/15 each  | ||||
Identification code | FR0010397232 | |||||
b) | Nature of the transaction | Acquisition of Ordinary Shares  | ||||
c) | Price(s) and volume(s) | Â
| ||||
d) | Aggregated information: · Aggregated volume · Price |  N/A Single transaction as above
  | ||||
e) | Date of the transaction | Â 15 May 2020 | ||||
f) | Place of the transaction | AIM | ||||
Â
Â
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name |  James Wakefield, Non-Executive Director & Chairman of the Board  | ||||
2. | Reason for the Notification | |||||
a) | Position/status | See 1(a) - classified as PDMRs of the Company  | ||||
b) | Initial notification/ Amendment | Initial Notification  | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Novacyt S.A. | ||||
b) | LEI | 213800BWAC2BF295EG28 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | ordinary shares of €1/15 each  | ||||
Identification code | FR0010397232 | |||||
b) | Nature of the transaction | Acquisition of Ordinary Shares  | ||||
c) | Price(s) and volume(s) | Â
| ||||
d) | Aggregated information: · Aggregated volume · Price |  N/A single transaction as above
  | ||||
e) | Date of the transaction | Â 15 May 2020 | ||||
f) | Place of the transaction | AIM Â | ||||
Â
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Â
- End -
Â
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
Â
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Â
FTI Consulting (International)
Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.comÂ
Â
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 47
arnaud.decheffontaines@fticonsulting.comÂ
Â
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
Â
For more information please refer to the website:Â www.novacyt.com
Â
Â